Review



assembler 7 software package  (DNASTAR)


Bioz Manufacturer Symbol DNASTAR manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    DNASTAR assembler 7 software package
    HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp <t>(HBV</t> <t>sequence</t> 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using <t>SeqMan</t> assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.
    Assembler 7 Software Package, supplied by DNASTAR, used in various techniques. Bioz Stars score: 90/100, based on 51 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/assembler 7 software package/product/DNASTAR
    Average 90 stars, based on 51 article reviews
    assembler 7 software package - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis"

    Article Title: Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis

    Journal: Antiviral research

    doi: 10.1016/j.antiviral.2019.104540

    HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp (HBV sequence 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using SeqMan assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.
    Figure Legend Snippet: HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp (HBV sequence 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using SeqMan assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.

    Techniques Used: Cell Culture, Purification, Sequencing, Amplification, Gel Purification, Plasmid Preparation, Transformation Assay, DNA Sequencing, Software, Mutagenesis



    Similar Products

    assembler 7 software package  (DNASTAR)
    90
    DNASTAR assembler 7 software package
    HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp <t>(HBV</t> <t>sequence</t> 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using <t>SeqMan</t> assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.
    Assembler 7 Software Package, supplied by DNASTAR, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/assembler 7 software package/product/DNASTAR
    Average 90 stars, based on 1 article reviews
    assembler 7 software package - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp (HBV sequence 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using SeqMan assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.

    Journal: Antiviral research

    Article Title: Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis

    doi: 10.1016/j.antiviral.2019.104540

    Figure Lengend Snippet: HepAD38 cells (1.0 X 105 cells per well) were plated in a 24-well plate 24 h prior to virus-producing induction. Five days following removal of tetracycline from cultured HepAD38 cells and cell treatment with 10 nM gemcitabine, 50 μM 5-aza-dC, 200 μM 5-aza-C or the combination of 5-aza-dC/5-aza-C with gemcitabine, HBV rcDNA was purified from cell culture supernatants. A DNA product of 714 bp (HBV sequence 87–800) was amplified by PCR. After gel purification, the 714 bp product was ligated to the pGEM-T vector. Ligated DNAs introduced into E. coli by transformation, and insert containing-vectors were subjected to DNA sequencing, with 70 −100 colonies were sequenced per each treatment (see Supplemental Table 1). Sequence alignments were done by using SeqMan assembly tool in the Lasergene 7 software package (DNAStar; Madison, WI). A. Mutation frequency analysis. Mutation frequency was calculated by the number of mutations divided by the total number of bases sequenced. The mutation frequency of the untreated was 1.46 × 10−4 mutations per basepair (see Supplemental Table 1). B. Mutation spectra analysis. The spectra of mutations from each experimental group is depected by a pie chart, which shows the main mutation types and percentages observed. The size of the pie chart was normalized to the mutation frequency of untreated controls. Results are shown from 3 independent experiments. The gray asterisks and brackets associating any two bars indicate the significant difference between the experimental pairs. The statistical significance compared to the untreated control is shown above the bar with black asterisks. Significance was analyzed with the “N-1” Chi-squared test; “ns” = not significant; “****” = p ≤ 0.0001; “**” = p ≤ 0.01; “*” = p ≤ 0.05. Abbreviation: gem = gemcitabine.

    Article Snippet: Sequence alignments were performed using SeqMan assembler of Lasergene 7 software package (DNAStar; Madison, WI).

    Techniques: Cell Culture, Purification, Sequencing, Amplification, Gel Purification, Plasmid Preparation, Transformation Assay, DNA Sequencing, Software, Mutagenesis